210 related articles for article (PubMed ID: 23577182)
1. Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study.
Debono M; Chadarevian R; Eastell R; Ross RJ; Newell-Price J
PLoS One; 2013; 8(4):e60984. PubMed ID: 23577182
[TBL] [Abstract][Full Text] [Related]
2. MIFEPRISTONE TREATMENT FOR MILD AUTONOMOUS CORTISOL SECRETION DUE TO ADRENAL ADENOMAS: A PILOT STUDY.
Belokovskaya R; Ravikumar A; Arumugam D; Izadmehr S; Goddard GM; Geer EB; Levine AC
Endocr Pract; 2019 Aug; 25(8):846-853. PubMed ID: 31070948
[No Abstract] [Full Text] [Related]
3. Resetting the Abnormal Circadian Cortisol Rhythm in Adrenal Incidentaloma Patients With Mild Autonomous Cortisol Secretion.
Debono M; Harrison RF; Chadarevian R; Gueroult C; Abitbol JL; Newell-Price J
J Clin Endocrinol Metab; 2017 Sep; 102(9):3461-3469. PubMed ID: 28911138
[TBL] [Abstract][Full Text] [Related]
4. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma.
Fernández-Real JM; Engel WR; Simó R; Salinas I; Webb SM
Clin Endocrinol (Oxf); 1998 Jul; 49(1):53-61. PubMed ID: 9797847
[TBL] [Abstract][Full Text] [Related]
5. The functional status of incidentally discovered bilateral adrenal lesions.
Androulakis II; Kaltsas GA; Markou A; Tseniklidi E; Kafritsa P; Pappa T; Papanastasiou L; Piaditis GP
Clin Endocrinol (Oxf); 2011 Jul; 75(1):44-9. PubMed ID: 21521282
[TBL] [Abstract][Full Text] [Related]
6. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study.
Deutschbein T; Reimondo G; Di Dalmazi G; Bancos I; Patrova J; Vassiliadi DA; Nekić AB; Debono M; Lardo P; Ceccato F; Petramala L; Prete A; Chiodini I; Ivović M; Pazaitou-Panayiotou K; Alexandraki KI; Hanzu FA; Loli P; Yener S; Langton K; Spyroglou A; Kocjan T; Zacharieva S; Valdés N; Ambroziak U; Suzuki M; Detomas M; Puglisi S; Tucci L; Delivanis DA; Margaritopoulos D; Dusek T; Maggio R; Scaroni C; Concistrè A; Ronchi CL; Altieri B; Mosconi C; Diamantopoulos A; Iñiguez-Ariza NM; Vicennati V; Pia A; Kroiss M; Kaltsas G; Chrisoulidou A; Marina LV; Morelli V; Arlt W; Letizia C; Boscaro M; Stigliano A; Kastelan D; Tsagarakis S; Athimulam S; Pagotto U; Maeder U; Falhammar H; Newell-Price J; Terzolo M; Fassnacht M
Lancet Diabetes Endocrinol; 2022 Jul; 10(7):499-508. PubMed ID: 35533704
[TBL] [Abstract][Full Text] [Related]
7. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
[TBL] [Abstract][Full Text] [Related]
8. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion.
Androulakis II; Kaltsas GA; Kollias GE; Markou AC; Gouli AK; Thomas DA; Alexandraki KI; Papamichael CM; Hadjidakis DJ; Piaditis GP
J Clin Endocrinol Metab; 2014 Aug; 99(8):2754-62. PubMed ID: 24712565
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiological Link between Insulin Resistance and Adrenal Incidentalomas.
Higgs JA; Quinn AP; Seely KD; Richards Z; Mortensen SP; Crandall CS; Brooks AE
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457158
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of new recommendations for adrenal incidentalomas in the evaluation of excessive cortisol secretion and follow-up.
Ruiz A; Michalopoulou T; Megia A; Näf S; Simón-Muela I; Solano E; Martínez L; Vendrell J
Eur J Clin Invest; 2019 Feb; 49(2):e13048. PubMed ID: 30412278
[TBL] [Abstract][Full Text] [Related]
11. Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up.
Papanastasiou L; Alexandraki KI; Androulakis II; Fountoulakis S; Kounadi T; Markou A; Tsiavos V; Samara C; Papaioannou TG; Piaditis G; Kaltsas G
Clin Endocrinol (Oxf); 2017 Apr; 86(4):488-498. PubMed ID: 27992961
[TBL] [Abstract][Full Text] [Related]
12. Luteinizing hormone and insulin resistance in menopausal patients with adrenal incidentalomas: The cause-effect relationship?
Marina LV; Ivović M; Tančić-Gajić M; Arizanović Z; Raković D; Milin-Lazović J; Kendereški A; Micić D; Vujović S
Clin Endocrinol (Oxf); 2018 Apr; 88(4):541-548. PubMed ID: 29288564
[TBL] [Abstract][Full Text] [Related]
13. Alterations in hypothalamic-pituitary-adrenal function immediately after resection of adrenal adenomas in patients with Cushing's syndrome and others with incidentalomas and subclinical hypercortisolism.
Khawandanah D; ElAsmar N; Arafah BM
Endocrine; 2019 Jan; 63(1):140-148. PubMed ID: 30259310
[TBL] [Abstract][Full Text] [Related]
14. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas.
Valli N; Catargi B; Ronci N; Vergnot V; Leccia F; Ferriere JM; Chene G; Grenier N; Laurent F; Tabarin A
Eur J Endocrinol; 2001 Apr; 144(4):401-8. PubMed ID: 11275951
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome.
Reincke M; Nieke J; Krestin GP; Saeger W; Allolio B; Winkelmann W
J Clin Endocrinol Metab; 1992 Sep; 75(3):826-32. PubMed ID: 1517373
[TBL] [Abstract][Full Text] [Related]
16. Depression: another cortisol-related comorbidity in patients with adrenal incidentalomas and (possible) autonomous cortisol secretion.
Šojat AS; Dunjić-Kostić B; Marina LV; Ivović M; Radonjić NV; Kendereški A; Ćirković A; Tančić-Gajić M; Arizanović Z; Mihajlović S; Vujović S
J Endocrinol Invest; 2021 Sep; 44(9):1935-1945. PubMed ID: 33528757
[TBL] [Abstract][Full Text] [Related]
17. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing's syndrome.
Tsagarakis S; Kokkoris P; Roboti C; Malagari C; Kaskarelis J; Vlassopoulou V; Alevizaki C; Thalassinos N
Clin Endocrinol (Oxf); 1998 May; 48(5):627-33. PubMed ID: 9666875
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study.
Di Dalmazi G; Vicennati V; Pizzi C; Mosconi C; Tucci L; Balacchi C; Cosentino ER; Paolisso P; Fanelli F; Gambineri A; Pelusi C; Repaci A; Garelli S; Galiè N; Borghi C; Golfieri R; Pagotto U
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32413902
[TBL] [Abstract][Full Text] [Related]
19. ACTH following overnight dexamethasone suppression can be used in the verification of autonomous cortisol secretion in patients with adrenal incidentalomas.
Puvaneswaralingam S; Kjellbom A; Lindgren O; Löndahl M; Olsen H
Clin Endocrinol (Oxf); 2021 Feb; 94(2):168-175. PubMed ID: 33108675
[TBL] [Abstract][Full Text] [Related]
20. Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients.
Kling MA; Demitrack MA; Whitfield HJ; Kalogeras KT; Listwak SJ; DeBellis MD; Chrousos GP; Gold PW; Brandt HA
Neuroendocrinology; 1993 Jun; 57(6):1082-91. PubMed ID: 8232766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
